Thus, the PROPHECY multicenter, prospective-blinded study of prostate cancer patients with high-risk mCRPC starting Abiraterone or Enzalutamide treatment, incvestigated the prognostic significance of baseline AR-V7 on clinical progression-free survival [209]. Here, AR is linked to prostate carcinoma.